KyungDong Pharm home
Prescription Medicines

Bazetop Tab. 20mg

Product Category
Osteoporosis treatment
Active Ingredients
Bazedoxyphene acetate
Appearance
A white or grayish-white, capsule-shaped, film-coated tablet.
Reimbursement Code
648104460
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Bazedoxifene acetate (in-house specification) ······ 22.6mg (20mg as Bazedoxifene)
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate, Opadry white (03B28796), sodium starch glycolate, colloidal silicon oxide, polysorbate 80

2. Effectiveness
Treatment and prevention of osteoporosis in postmenopausal women
However, although this drug reduced the incidence of spinal fractures, its effectiveness for non-vertebral fractures has not been established.

3. Dosage and dosage
Take 1 tablet (20mg as bazedoxifene) once a day, regardless of meal.
Patients should take calcium and vitamin D supplements if dietary intake is inadequate.
Patients with renal impairment: This drug has not been sufficiently evaluated in patients with severe renal impairment and should be administered with caution. No dose adjustment is necessary in patients with mild or moderate renal impairment.
Patients with hepatic impairment: This drug is not recommended for use in patients with hepatic impairment as its safety and efficacy have not been established.

4. Precautions for use
1. Warning
1) This drug increases the risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism, retinal vein thrombosis). Venous thromboembolism was most commonly reported in the first year of treatment. Other venous thromboembolic events may also occur. Therefore, this drug is not recommended for women at high risk for venous thromboembolic events. Risk factors associated with venous thromboembolism (VTE) in clinical trials were: Old age, obesity, immobility, surgery, major trauma and malignancy. Because immobility increases the risk of venous thromboembolic events regardless of treatment with this drug, this drug should be discontinued before prolonged immobility (e.g., postoperative recovery, prolonged bed rest) begins, and treatment should be restarted when the patient is fully mobile. Additionally, women taking this medication should move their bodies regularly during long trips.
2) This drug can only be administered to postmenopausal women. This drug has not been studied in premenopausal women and its safety has not been established, so its administration is not recommended.
3) There is no evidence that this drug causes endometrial hyperplasia. Any uterine bleeding occurring during treatment with this drug is unexpected and should be fully investigated by a specialist.
4) The safety of this drug in breast cancer patients has not been studied. Because there are no data on concomitant use with drugs used to treat early or advanced breast cancer, the use of this drug for the prevention or treatment of breast cancer is not recommended.

2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug or its components
2) Patients with or with a history of venous thromboembolism (deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, etc.)
3) Pregnant women and women of childbearing potential who may become pregnant
4) Nursing mothers
5) Patients with uterine bleeding of unknown cause
6) Patients with symptoms or signs of endometrial cancer (safety in these patients has not been adequately studied).
7) This medicine contains lactose. Patients with rare genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medication.

3. Administer with caution to the following patients:
1) Patients with hypertriglyceridemia (This drug has not been studied in women with triglyceride levels exceeding 300 mg/dL (3.4 mmol/L) and may increase serum triglyceride concentration.)
2) Patients with severe renal impairment
3) Patients with hepatic impairment (administration is not recommended because the area under the blood concentration-time curve (AUC) increased by an average of 4.3 times in patients with hepatic impairment compared to normal subjects.)

4. Adverse reactions
1) Safety was evaluated in two multicenter, double-blind, randomized, placebo- and active-controlled phase 3 trials. The first was a 2-year osteoporosis prevention trial involving 1,583 postmenopausal women: 321 received bazedoxifene 10 mg, 322 received bazedoxifene 20 mg, 319 received bazedoxifene 40 mg, 311 received raloxifene 60 mg, and 310 received placebo. The second was a 3-year osteoporosis treatment trial involving 7,492 postmenopausal women: 1,886 received bazedoxifene 20 mg, 1,872 received bazedoxifene 40 mg, 1,849 received raloxifene 60 mg, and 1,885 received placebo.
Most adverse events in these clinical trials were mild to moderate in severity and did not result in treatment discontinuation. In clinical trials for osteoporosis treatment, 14.5% of the bazedoxifene-treated group and 13.3% of the placebo-treated group, and in osteoporosis prevention clinical trials, 17.1% of the bazedoxifene-treated group and 15.5% of the placebo-treated group discontinued medication due to adverse reactions.
The most common adverse reactions leading to treatment discontinuation were vasodilation (hot flushes) and leg cramps.
The safety data in the following table were obtained from clinical trials and post-marketing surveillance.
<Adverse reaction table>
※ Table: Refer to attached document
2) Post-marketing adverse reactions
Ocular cases other than retinal vein thrombosis have been reported post-marketing and include decreased vision, blurred vision, photopsia, visual field defects, visual disturbances, nystagmus, eyelid edema, blepharospasm, eye pain, and eye swelling. The underlying reason for these cases is unclear. If eye symptoms occur, you should seek medical attention.
3) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,423 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 6.11% (209/3,423 people, 261 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
※ Table: Refer to attached document
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
※ Table: Refer to attached document

5. General precautions
1) Effects on ability to drive and use machines
(1) There have been no tests conducted on the effects when driving or using machinery. However, because drowsiness has been reported as an adverse reaction in clinical trials, patients should be informed in advance about the potential effects when driving or using machinery.
(2) Patients may experience vision symptoms such as impaired vision or blurred vision. If these symptoms occur, patients should avoid driving or operating machinery that requires precise visual perception until these symptoms resolve or until they are cleared by a doctor.

6. Interaction
1) In a test conducted for 30 days, bazedoxifene increased the concentration of hormone-binding globulins such as corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG), and thyroxine-binding globulin (TBG).
2) Bazedoxifene is hardly metabolized through cytochrome P450 (CYP). This drug does not induce or inhibit the activity of major CYP isoenzymes. Based on in vitro data, this drug is unlikely to interact with co-administered medications via CYP-mediated metabolism. However, no trials have been conducted on humans.
3) No significant pharmacokinetic interactions were observed between this drug and the following drugs; Antacids containing ibuprofen, azithromycin, aluminum and magnesium hydroxide.
4) Co-administration of this drug (40 mg daily) and atorvastatin (20 mg single dose) in healthy postmenopausal women did not affect the pharmacokinetics of this drug, atorvastatin, or its active metabolite.
5) Based on the plasma protein binding characteristics of bazedoxifene observed in vitro, it is unlikely to interact with warfarin, digoxin, and diazepam.
6) This drug is metabolized through the enzyme UGT (uridine diphosphate glucuronosyltransferase) in the intestines and liver. Co-administration with drugs known to induce UGT enzymes, such as rifampin, phenobarbital, carbamazepine, and phenytoin, may increase the metabolism of this drug and potentially decrease its systemic concentrations.

7. Administration to pregnant and lactating women
1) This drug should only be used in postmenopausal women.
2) Pregnant women: Pregnant women and women of childbearing potential should not take this drug. There are no data regarding the use of this drug in pregnant women. Reproductive toxicity has been observed in tests on animals, and it has been shown that it may have harmful effects on the fetus. The potential risk in humans is unknown. If you become pregnant while taking the drug, you must inform the patient of the potential harm to the fetus and stop taking this drug immediately.
3) Nursing mothers: It is not known whether this drug is excreted in human milk. This medicine should not be used in breastfeeding women.
4) Fertility: In a study on female rats, adverse reactions in estrous cycle and fertility were observed.

8. Administration to children
This drug is not used in children.

9. Administration to elderly people
No dosage adjustment according to age is necessary. In a study involving 26 healthy postmenopausal women, the pharmacokinetics of a single 20 mg dose of bazedoxifene were evaluated. On average, AUC was found to increase 1.5 times in women aged 65-74 (n=8) compared to women aged 51-64 (n=8), and AUC increased 2.3-fold in women aged 75 or older (n=8). This increase in AUC is likely due to changes in liver function with age.

10. Treatment in case of overdose
In case of overdose, there is no special antidote and symptomatic treatment is provided.

11. Storage and handling precautions
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.

12. Pharmaceutical equivalence test information
A. As a result of measuring the blood bazedoxifene in the blood of 45 people, one tablet each was administered orally on an empty stomach to healthy adults in a 2x2 cross-over study of the test drug, Viviant Tab. 20 mg (Bazedoxyphene Acetate) (Huons Co., Ltd.) and the reference drug, Viviant Tab. 20 milligram (Bazedoxyphene Acetate) (Pfizer Korea Pharmaceutical Co., Ltd.). As a result, the comparative evaluation value (AUCt, When Cmax) was log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log0.8 to log1.25, demonstrating biological equivalence.
※ Table: Refer to attached document

13. Others
1) Carcinogenicity
(1) In a 6-month carcinogenicity test targeting transgenic mice, benign ovarian granulosa cell tumors increased when administered to female mice at 150 mg/kg/day or 500 mg/kg/day. The systemic exposure (AUC) to bazedoxifene in this group was 35- and 69-fold higher compared to postmenopausal women receiving bazedoxifene at 20 mg/day for 14 days.
(2) In a 2-year carcinogenicity test on rats, ovarian granulosa cell-positive tumors increased when administered to female rats at dietary concentrations of 0.03% and 0.1%. The systemic exposure (AUC) to bazedoxifene in this group was 2.6- and 6.6-fold higher compared to postmenopausal women receiving bazedoxifene at 20 mg/day for 14 days.
(3) In male rats, bazedoxifene induced cortico-medullary nephrocalcinosis and increased spontaneous chronic progressive nephropathy (CPN). Urine test values ​​showed pathological changes. In long-term trials, renal tumors (adenocarcinomas and carcinomas) were observed at all doses tested, most likely as a result of chronic kidney damage. In a 2-year carcinogenicity study, male and female rats administered orally to bazedoxifene contained in food at rates of 0, 0.003%, 0.01%, 0.03%, and 0.1% were exposed to approximately 0.6-23 and 0.9-31 times the clinical dose of 20 mg, respectively, based on surface area (mg/m2). Because chronic progressive nephropathy and corticomedullary nephrocalcinosis are likely kidney diseases limited to rats, these results are unlikely to be relevant to humans.
(4) In an 18-month bone effectiveness test targeting old monkeys (Macaca fascicularis) with their ovaries removed, when bazedoxifene was administered orally at 0, 0.2, 0.5, 1, 5, and 25 mg/kg/day, exposure was found to be approximately 0.2-24 times the clinical dose of 20 mg based on surface area (mg/m2). Renal cell carcinoma was observed in this experiment. This tumor is considered a spontaneous renal cell carcinoma known to occur in non-human primates and is not believed to be of human relevance.
2) Mutagenicity
(1) This drug was not genotoxic or mutagenic in tests including in vitro bacterial reverse mutation test, in vitro mammalian cell forward mutation test (thymidine kinase (TK+/-) locus in mouse lymphoma L5178Y cells), chromosomal aberration test in in vitro Chinese hamster ovary (CHO) cells, and in vivo mouse micronucleus test.
3) Fertility abnormalities
(1) In a test on rabbits, when administered at a maternally toxic dose of 0.5 mg/kg/day (1.5 times the human exposure) or higher, an increase in miscarriage, fetal heart abnormalities (ventricular septal defect), and skeletal system abnormalities (mainly delayed ossification of the spine and skull and bone deformities) was observed. In experiments on rats, when administered at a maternally toxic dose of 1 mg/kg/day (0.3 times the human exposure dose) or more, a decrease in the number of viable fetuses and a decrease in fetal weight were observed. No abnormalities in fetal development were observed.
(2) In a fertility test on female rats, when administered at 0.3-30mg/kg/day (0.03-8 times the human exposure dose) before and during the mating period, bazedoxifene had a negative effect on the estrous cycle and fertility in all females administered.

5. How to save
Airtight container, stored below 25℃

6. Packaging unit
30 tablets/PTP (10 tablets/PTPX3)

7. Period of use
18 months from date of manufacture